- [Bamlanivimab EUA Letter of Authorization]($$CMS_PREFIX$$downloads/press-release/Lilly202011101.pdf)
- [Bamlanivimab EUA Letter of Authorization FAQ]($$CMS_PREFIX$$downloads/press-release/Lilly202011102.pdf)
- [Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirementIFN Lambda EigerBioPharmaceuticals]($$CMS_PREFIX$$downloads/press-release/RegeneronEiger2020103017.pdf)
- [Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention]($$CMS_PREFIX$$downloads/press-release/Regeneron20201028.pdf)
- [Lilly Statement Regarding NIHâ€™s ACTIV-3 Clinical Trial]($$CMS_PREFIX$$downloads/press-release/Lilly20201027.pdf)
- [IFN Lambda EigerBioPharmaceuticals]($$CMS_PREFIX$$downloads/press-release/Eiger20201017.pdf)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7]($$CMS_PREFIX$$Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7]($$CMS_PREFIX$$Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7]($$CMS_PREFIX$$https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010072.pdf)
- [Synairgen plc, Interim results for the six months ended 30 June 2020]($$CMS_PREFIX$$downloads/press-release/Synairgen20200930.pdf)
- [Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting]($$CMS_PREFIX$$downloads/press-release/Lilly20200930.pdf)
- [Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients]($$CMS_PREFIX$$downloads/press-release/Regeneron20200930.pdf)
<!--stackedit_data:
eyJoaXN0b3J5IjpbLTE0NDA4OTA2NjRdfQ==
-->